Another factor responsible for the heterogeneity of the NMIBC patients is the reported correlation of the tumor cells and their infiltrated immunocytes to express checkpoint ligands (PD-L1) of their receptor (PD-1), which raises the chance of the antitumor immunological therapy [50,51]. Here, CD274 is linked to neoplasm.